Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 128Breast 10Tumor-Agnostic 6Gynecologic 3Gastrointestinal 3Thoracic 2

Conditions

Recurrent Endometrial Endometrioid Adenocarcinoma 1Ovarian Neoplasms 1Advanced Epithelial Ovarian 1

Interventions

Paclitaxel 264Carboplatin 246Cisplatin 153Bevacizumab 104Gemcitabine 78Topotecan 77liposomal doxorubicin 67pembrolizumab 60Docetaxel 56Cyclophosphamide 50Taxes 48Radiotherapy 44olaparib 43Surveys and Questionnaires 43Doxorubicin 43Filgrastim 42Brachytherapy 37Drug Therapy 31niraparib 28Blood Specimen Collection 28Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 26human papillomavirus vaccine, L1 type 16, 18 24Peripheral Blood Stem Cell Transplantation 23atezolizumab 22Oxaliplatin 22Pemetrexed 21Nivolumab 21Hyperthermic Intraperitoneal Chemotherapy 21Etoposide 21Immunoglobulin G 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × enzalutamide × Gynecologic × Clear all
NCT02684227 2025-03-19

Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
50 enrolled 14 charts
Gynecologic

Recurrent Endometrial Endometrioid Adenocarcinoma

NCT01974765 2023-04-28

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
59 enrolled 11 charts
Gynecologic

Advanced Epithelial Ovarian

NCT03464201 2023-02-22

GREKO III

Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes

Phase 2 Completed
16 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔